A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Clinical trial NCT06634589 · RECRUITING
Trial details
- NCT number
- NCT06634589
- Sponsor
- BeOne Medicines
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-27
- Primary completion
- 2028-12-02
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.